A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

NCT01928615 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Problems with drug supply

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab - intravenous solution
DRUG: Trastuzumab - subcutaneous solution
DRUG: Chemotherapy

Sponsor

Hoffmann-La Roche